Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-09-13
2011-10-25
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C424S130100, C424S141100
Reexamination Certificate
active
08044179
ABSTRACT:
Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin.
REFERENCES:
patent: 6383808 (2002-05-01), Freier
patent: 6464975 (2002-09-01), Millis
patent: 6900187 (2003-09-01), Gleave
patent: 7279294 (2003-11-01), Morin
patent: 7285541 (2004-04-01), Gleave
patent: 6812339 (2004-11-01), Venter
patent: 7691382 (2007-05-01), Dobson
patent: 7309487 (2007-12-01), Inana
patent: 7597888 (2008-02-01), Gill
patent: 7585937 (2008-05-01), Kungl
patent: 2003/0134301 (2003-07-01), Brooksbank et al.
patent: 2003/0162702 (2003-08-01), Millis
patent: 2003/0211476 (2003-11-01), O'Mahony
patent: 2004/0082534 (2004-04-01), Gleave
patent: 2004/0220131 (2004-11-01), Jackson
patent: 2004/0224914 (2004-11-01), Jackson
patent: 2005/0048490 (2005-03-01), Azimzai
patent: 2005/0152903 (2005-07-01), Newman
patent: 2005/0222027 (2005-10-01), Chiang
patent: 2005/0255114 (2005-11-01), Labat
patent: 2006/0029956 (2006-02-01), Beyer
patent: 2006/0088532 (2006-04-01), Helsinki et al.
patent: 2006/0122141 (2006-06-01), Gleave
patent: 2006/0251668 (2006-11-01), Goletz
patent: 2007/0015145 (2007-01-01), Woolf
patent: 2007/0042945 (2007-02-01), Bodary
patent: 2007/0082337 (2007-04-01), Sorek
patent: 2007/0083334 (2007-04-01), Mintz
patent: 2007/0099242 (2007-05-01), Heinecke
patent: 2007/0105114 (2007-05-01), Li
patent: 2007/0117746 (2007-05-01), Dobson
patent: 2007/0134260 (2007-06-01), Feger
patent: 2007/0224201 (2007-09-01), Wu
patent: 2008/0014198 (2008-01-01), Gleave
patent: 2008/0064651 (2008-03-01), Gleave
patent: 2008/0070995 (2008-03-01), Westbrook
patent: 2008/0119425 (2008-05-01), Gleave
patent: 2008/0253963 (2008-10-01), Morin
patent: 2008/0261912 (2008-10-01), Gleave
patent: 2008/0274996 (2008-11-01), Gleave
patent: 2008/0286834 (2008-11-01), Halenbeck
patent: 2008/0293070 (2008-11-01), Sekaly
patent: 2008/0307537 (2008-12-01), Bachoo
patent: 2008/0317771 (2008-12-01), Spagnoli
patent: 2009/0005541 (2009-01-01), Kungl
patent: 2009/0018026 (2009-01-01), Kim
patent: 2009/0048171 (2009-02-01), Dobson
patent: 2009/0053828 (2009-02-01), Regnier
patent: 2009/0081685 (2009-03-01), Beyer
patent: 2009/0117578 (2009-05-01), Metz
patent: 2009/0144839 (2009-06-01), Inana
patent: 2009/0181380 (2009-07-01), Belouchi
patent: 2009/0203639 (2009-08-01), Van Criekinge
patent: 2009/0208921 (2009-08-01), Tempst
patent: 2009/0215709 (2009-08-01), Van Criekinge
patent: 2009/0238832 (2009-09-01), Bodary-Winter
patent: 2009/0258089 (2009-10-01), Gleave
patent: 2009/0280124 (2009-11-01), Labat
patent: 2009/0292008 (2009-11-01), Gleave
patent: 2010/0075866 (2010-03-01), Hood
patent: 2010/0086541 (2010-04-01), Wu
patent: 1358326 (2002-09-01), None
patent: 1603514 (2004-08-01), None
patent: 2008100 (2007-01-01), None
patent: 1716227 (2007-04-01), None
patent: 2057465 (2008-02-01), None
patent: 2087152 (2008-05-01), None
patent: 1940457 (2008-07-01), None
patent: 2014675 (2009-01-01), None
patent: 2004521627 (2002-09-01), None
patent: 2004513626 (2007-05-01), None
patent: 2007535910 (2007-05-01), None
patent: 2008506123 (2008-02-01), None
patent: WO 91/05043 (1991-04-01), None
patent: WO9105043 (1991-04-01), None
patent: WO 00/34469 (2000-06-01), None
patent: WO0166689 (2001-09-01), None
patent: WO02072830 (2002-09-01), None
patent: WO03016475 (2003-02-01), None
patent: WO03054152 (2003-07-01), None
patent: WO2004005934 (2004-01-01), None
patent: WO2004050707 (2004-06-01), None
patent: WO2004066941 (2004-08-01), None
patent: WO2005016962 (2005-02-01), None
patent: WO2005049806 (2005-06-01), None
patent: WO2005060457 (2005-07-01), None
patent: WO 2005/080434 (2005-09-01), None
patent: WO2005080434 (2005-09-01), None
patent: WO2006035237 (2006-04-01), None
patent: WO2006081430 (2006-08-01), None
patent: WO2006089586 (2006-08-01), None
patent: WO2006113671 (2006-10-01), None
patent: PCT/CA2006/001505 (2006-12-01), None
patent: WO2007047995 (2007-04-01), None
patent: WO2007123976 (2007-11-01), None
patent: WO2008021290 (2008-02-01), None
patent: WO2008049239 (2008-05-01), None
patent: WO2008085035 (2008-07-01), None
patent: WO2008104808 (2008-09-01), None
patent: WO2009034562 (2009-03-01), None
patent: WO2009061382 (2009-05-01), None
patent: WO2009090553 (2009-07-01), None
patent: WO2009093246 (2009-07-01), None
patent: WO2009116860 (2009-09-01), None
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Paul. Fundamental Immunology, 3rdEdition, 1993. pp. 292-295.
Colman. Research in Immunology, 1994. vol. 145, pp. 33-36.
Miyake H. et al., Acquisition of Chemoresistant Phenotype by Overexpression . . . , Cancer Research 60, pp. 2547-2554, May 1, 2000.
So Alan et al., Antisense Oligonucloetide Therapy in the Managment of Bladder Cancer, Curr. Opin. Urol. 15, pp. 320-327, (2005).
Zellweger T. et al., Antitumor Activity of Antisense Clusterin Oligonucleotides . . . , The J. of Pharmacology and Experimental Therapeutics, 298, pp. 934-940 (2001).
Miyake H. et al., Introducing the Clusterin Gene Into Human Renal Cell Carninoma . . . , The Journal of Urology, 167 pp. 2203-2208 May 2002.
So A. et al., Knockdown of the Cytoprotective Chaperone, Clusterin, Chemosensitizes Human Breast Cancer Cells . . . Mol. Cancer Ther. 4 (12), pp. 1837-1849, Dec. 2005.
Park Dong C. et al., Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer, Neoplasia Press, vol. 10, pp. 964-972, Sep. 2008.
Miyake H. et al., Overexpression of Clusterin in Transitional Cell Carcinoma of the Bladder . . . , Urology, 59, pp. 150-154 Elsevier Science (2002).
Hara I. et al., Introduction of Clusterin Gene into Human Renal Cell Carcinoma Cells Enhances, Jpn. J. Cancer Res. 92, pp. 1220-1224, Nov. 2001.
Kurisaki et al.; Nuclear factor YY1 inhibits transforming growth factor beta- and bone morphogenetic protein-induced cell differentiation; Mol Cell Biol. (2003) 23:4494-510.
Li et al.; Predicting Protein Disorder for N-, C-, and Internal Regions. Genome Informatics (1999); 10: 30-40.
GenBank accession No. AAA30846, Hartmann, K. et al. J. Biol. Chem. 266 (15), pp. 9924-9931 (1991).
GenBank accession No. AAA31013, Diemer, V. J. Biol. Chem. 267 (8), pp. 5257-5264 (1992).
GenBank accession No. AAA35692, Jenne, D.E. and Tschopp, J. Journal Pr
Cantin Christiane
Lenferink Anne E. G.
O'Connor-McCourt Maureen D.
Forget Janique
Gussow Anne M.
National Research Council of Canada
LandOfFree
Methods and compositions for modulating tumor cell activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating tumor cell activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating tumor cell activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261211